Literature DB >> 7083724

Physiologic and temporal variation in hepatic elimination of midazolam.

U Klotz, G Ziegler.   

Abstract

Midazolam kinetics were evaluated in six healthy male subjects after single oral (15 mg)and intravenous (0.075 mg/kg) doses. The three-part randomized crossover study consisted of a morning dose in supine position (part A) and morning (part B) and evening (part C) doses under ambulant (sitting/walking) conditions. While no significant changes could be observed in the absorption and distribution process or the elimination half lives, total plasma clearance was higher during part A (616+/-157 ml/min, P=0.01) and C(463+/-82 ml/min, P=0.02), than in part B (317+/-110 ml/min, +/-SD). Since the intrinsic (oral) clearance was also higher during part A (1656+/-657 ml/min, P=0.003) and C(1310+/-579 ml/min, P=0.024) than during part B(710+/-241 ml/min), bioavailability did not change (range 37 to 44%). These data indicate that posture and circadian rhythm are important variables affecting blood flow-dependent hepatic elimination of midazolam.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7083724     DOI: 10.1038/clpt.1982.133

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  24 in total

1.  Lack of effect of subject posture on intravenous midazolam clearance: implications for hepatic cytochrome P450 3A phenotyping.

Authors:  Joseph D Ma; Anne N Nafziger; William Mylott; David B Haughey; Mario L Rocci; Joseph S Bertino
Journal:  Br J Clin Pharmacol       Date:  2008-12-12       Impact factor: 4.335

2.  Lack of effect of nitrendipine on the pharmacokinetics and pharmacodynamics of midazolam during steady state.

Authors:  J Handel; G Ziegler; A Gemeinhardt; H Stuber; C Fischer; U Klotz
Journal:  Br J Clin Pharmacol       Date:  1988-02       Impact factor: 4.335

3.  Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction.

Authors:  E D Kharasch; A Francis; A London; K Frey; T Kim; J Blood
Journal:  Clin Pharmacol Ther       Date:  2011-05-11       Impact factor: 6.875

4.  Pharmacokinetics from a dynamical systems point of view.

Authors:  J M van Rossum; J E de Bie; G van Lingen; H W Teeuwen
Journal:  J Pharmacokinet Biopharm       Date:  1989-06

5.  [Drugs for intravenous induction of anesthesia: ketamine, midazolam and synopsis of current hypnotics].

Authors:  E Halbeck; C Dumps; D Bolkenius
Journal:  Anaesthesist       Date:  2018-08       Impact factor: 1.041

6.  Dose dependent pharmacokinetics of midazolam.

Authors:  L D Bornemann; B H Min; T Crews; M M Rees; H P Blumenthal; W A Colburn; I H Patel
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

7.  Pharmacokinetics of midazolam in relation to polymorphic sparteine oxidation.

Authors:  U Klotz; G Mikus; C Zekorn; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

8.  Pharmacokinetics of midazolam and alpha-hydroxy-midazolam following rectal and intravenous administration.

Authors:  T G Clausen; J Wolff; P B Hansen; F Larsen; S N Rasmussen; J S Dixon; C Crevoisier
Journal:  Br J Clin Pharmacol       Date:  1988-04       Impact factor: 4.335

9.  The pharmacokinetics of midazolam in patients with congestive heart failure.

Authors:  I H Patel; P P Soni; E K Fukuda; D F Smith; C V Leier; H Boudoulas
Journal:  Br J Clin Pharmacol       Date:  1990-05       Impact factor: 4.335

Review 10.  Time-dependence in benzodiazepine pharmacokinetics. Mechanisms and clinical significance.

Authors:  T W Guentert
Journal:  Clin Pharmacokinet       Date:  1984 May-Jun       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.